Zero incidence of factor VIII inhibitors and successful haemostatic response in previously factor VIII‐treated patients with haemophilia A switching to turoctocog alfa in a noninterventional study - Escuriola Ettingshausen - - Haemophilia -
Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa - Santagostino - 2014 - Haemophilia - Wiley Online Library
Interim results from a large multinational extension trial (guardian™2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A - Lentz - 2016 - Haemophilia - Wiley Online Library
PDF) von Willebrand Factor-binding aptamer rondoraptivon pegol as treatment for severe and non-severe hemophilia A
Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial - Yaish -
PDF) Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial
PDF) Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial
Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review - Hassan - 2018 - Journal of Thrombosis and Haemostasis - Wiley Online Library
PDF) Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A
PDF) Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A
Updates from guardian<sup>â—¢</sup>: a comprehensive registration programme
Efficient and safe correction of hemophilia A by lentiviral vector-transduced BOECs in an implantable device: Molecular Therapy - Methods & Clinical Development
PDF) Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial
Efficient and safe correction of hemophilia A by lentiviral vector-transduced BOECs in an implantable device - ScienceDirect
Efficient and safe correction of hemophilia A by lentiviral vector-transduced BOECs in an implantable device - ScienceDirect
Turoctocog alfa is safe for the treatment of Indian patients with hemophilia A: Guardian 10 trial results - John - 2020 - Research and Practice in Thrombosis and Haemostasis - Wiley Online Library
Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study - Lentz - 2022 - Research and Practice in
Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 p
Supplementary Appendix 2020.01.27 R2
Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study - Lentz - 2022 - Research and Practice in
Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study - Lentz - 2022 - Research and Practice in
PDF) Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: Insights from two clinical trials on turoctocog alfa
Long‐term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial - Lentz - 2018 - Haemophilia - Wiley Online Library
Efficient and safe correction of hemophilia A by lentiviral vector-transduced BOECs in an implantable device: Molecular Therapy - Methods & Clinical Development
Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial - Yaish -
Full article: Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden
PDF) Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial
Efficient and safe correction of hemophilia A by lentiviral vector-transduced BOECs in an implantable device: Molecular Therapy - Methods & Clinical Development